Management Options for Persistent Postoperative Acromegaly
- 9 August 2012
- journal article
- review article
- Published by Elsevier in Neurosurgery Clinics of North America
- Vol. 23 (4) , 621-638
Abstract
No abstract availableKeywords
This publication has 105 references indexed in Scilit:
- Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysisPituitary, 2011
- Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegalyPituitary, 2011
- Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature reviewPituitary, 2010
- Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegalyPituitary, 2009
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionPituitary, 2009
- Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic reviewPituitary, 2009
- Control of IGF‐I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegalyClinical Endocrinology, 2008
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Long‐term (up to 18 years) effects on GH/IGF‐1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH‐secreting pituitary adenoma responsive to SSTaClinical Endocrinology, 2007
- Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trialClinical Endocrinology, 2006